FAST NEWS: Clover Bio Gets Exclusive Rights for Imported Flu Vaccine
The latest: Clover Biopharmaceuticals Ltd. (2197.HK) said on Monday it has reached an exclusive agreement to import Adimmune Corp.’s quadrivalent seasonal influenza vaccine AdimFlu-S (QIS) to China. It added it will…
RELATED ARTICLES
-
Dispute over Covid vaccines casts doubt on Clover Bio recovery
2197.HK -
Zhengye Biotech’s ‘pet-sized’ IPO leaves plenty of room for more fundraising
ZYBT.US
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
WuXi Biologics sells vaccine plant as new U.S. law looms
2269.HK
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
- Mao Geping’s Hong Kong IPO gets lift from regulatory nod
